This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pharmspective Launches Affordable Care Act Knowledge And News Hub For Healthcare Decision-Makers

NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Pharmspective, LLC announced the launch today of HealthcareReformInsider.com, a knowledge and news hub for key stakeholders impacted by the Affordable Care Act (ACA).  HealthcareReformInsider.com will aggregate news, research, policy analysis, and government directives on the ACA for key decision makers assessing upcoming strategic choices driven by implementation of the ACA.   Pharmspective provide market research and knowledge management applications to the pharmaceutical industry.

"We set out to simplify the acquisition of Healthcare Reform information for key decision makers when we designed HealthcareReformInsider.com," stated Katie Derdeyn, M.D., Managing Partner & Co-Founder of Pharmspective.  "There is a real need for an information portal that vets everything that's written about the ACA and extracts what's relevant for building strategies for leading healthcare organizations. HealthcareReformInsider.com will do that and ensure that its users are up-to-date on the latest key developments involving the Affordable Care Act."

By honing in on the emerging and evolving insurer entities (State Exchanges, Medicaid, and Medicare) that will drive expansion of coverage, the new healthcare models that will drive changes in how care is provided (ACOs, Community Health Centers, Medical Homes, etc.), and the regulations that will influence payment (MLR rules, Individual Mandate, Quality-based Incentives, etc.), HealthcareReformInsider.com provides a destination for knowledge acquisition related to this expansive legislation.

"Our experience in helping healthcare organizations understand the ACA has allowed us to construct a site that provides the most relevant and current ACA news and policy analysis," said Stephen Reid, Managing Partner and leader of Pharmspective's Healthcare Reform practice.  "Following HealthcareReformInsider.com on the web and on Twitter (@hcrinsider) will keep healthcare decision-makers informed on the latest ACA developments that impact their market strategies."

About Pharmspective: Pharmspective, LLC (pharmspective.com) is a Specialty Therapeutics Market Research firm providing commercial insights and knowledge management applications for the biopharmaceutical industry. The company is uniquely focused on understanding the buying process for specialty therapeutics through syndicated market research studies examining clinical decision-making, drug acquisition, access and reimbursement, and therapy administration for specialty therapeutics in autoimmune diseases and Oncology. Pharmspective's Healthcare Reform team provides insights into the Affordable Care Act through its proprietary ClearView knowledge management application, market assessments of the impact of key ACA provisions on healthcare decision-makers, and its HealthCareReformInsider.com website. The company maintains offices in New York City and St. Louis, MO.  Follow Pharmspective on Twitter at twitter.com/Pharmspective and follow HealthcareReformInsider.com on Twitter at twitter.com/hcrinsider.

Contact: Cindy Wong Tel: 314-814-2729 x1003 cindy.wong@Pharmspective.com.

SOURCE Pharmspective, LLC

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,957.84 -125.96 -0.74%
S&P 500 1,976.88 -11.10 -0.56%
NASDAQ 4,444.5590 -27.5490 -0.62%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs